Found: 19
Select item for more details and to access through your institution.
Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage.
- Published in:
- Neuro-Oncology Practice, 2017, v. 4, n. 1, p. 24, doi. 10.1093/nop/npw008
- By:
- Publication type:
- Article
Diagnosis and treatment of primary central nervous system lymphoma.
- Published in:
- Current Oncology Reports, 2005, v. 7, n. 1, p. 47, doi. 10.1007/s11912-005-0025-x
- By:
- Publication type:
- Article
Primary central nervous system lymphoma.
- Published in:
- Current Oncology Reports, 2004, v. 6, n. 5, p. 388, doi. 10.1007/s11912-004-0065-7
- By:
- Publication type:
- Article
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 1, p. 134, doi. 10.1093/neuonc/noaa152
- By:
- Publication type:
- Article
PATH-49. GENOMIC ATTRIBUTES OF TUMOR EVOLUTION AND TREATMENT RESPONSE IN DIFFUSE GLIOMA.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi169, doi. 10.1093/neuonc/noy148.703
- By:
- Publication type:
- Article
A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 6, p. 873, doi. 10.1093/neuonc/nov301
- By:
- Publication type:
- Article
Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 5, p. 735, doi. 10.1093/neuonc/nov268
- By:
- Publication type:
- Article
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
- Published in:
- Neuro-Oncology, 2015, v. 17, n. 1, p. 116, doi. 10.1093/neuonc/nou148
- By:
- Publication type:
- Article
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
- Published in:
- Neuro-Oncology, 2013, v. 15, n. 2, p. 242, doi. 10.1093/neuonc/nos295
- By:
- Publication type:
- Article
Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
- Published in:
- Annals of Clinical & Translational Neurology, 2020, v. 7, n. 4, p. 429, doi. 10.1002/acn3.51009
- By:
- Publication type:
- Article
Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.
- Published in:
- Journal of Neuro-Oncology, 2019, v. 145, n. 1, p. 57, doi. 10.1007/s11060-019-03266-0
- By:
- Publication type:
- Article
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
- Published in:
- Journal of Neuro-Oncology, 2019, v. 144, n. 2, p. 403, doi. 10.1007/s11060-019-03243-7
- By:
- Publication type:
- Article
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
- Published in:
- Journal of Neuro-Oncology, 2012, v. 109, n. 2, p. 385, doi. 10.1007/s11060-012-0905-5
- By:
- Publication type:
- Article
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
- Published in:
- Journal of Neuro-Oncology, 2008, v. 87, n. 1, p. 85, doi. 10.1007/s11060-007-9491-3
- By:
- Publication type:
- Article
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
- Published in:
- Journal of Neuro-Oncology, 2007, v. 85, n. 2, p. 217
- By:
- Publication type:
- Article
In Reply.
- Published in:
- 2013
- By:
- Publication type:
- Letter
Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment.
- Published in:
- Oncologist, 2012, v. 17, n. 2, p. 274, doi. 10.1634/theoncologist.2011-0198
- By:
- Publication type:
- Article